预约演示
Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany
2024-02-20
并购抗体药物偶联物
An expansion process has already kicked off in Germany, with work on the project expected to wrap up by 2030 “at the latest,” Daiichi Sankyo said last week.
After laying out plans to absorb a pair of production subsidiaries in October, Japan’s Daiichi Sankyo is doubling down on its Daiichi Sankyoate the red-hot antibody-drug conjugate (ADC) field.
Aiming to create an “international innovation center,” Daiichi is plugging roughly 1 biDaiichi Sankyo1.08 billion) into an expansion of its production and development site in Pfaffenhofen an der Ilm, just north of the company’s European headquarters in Munich.
The project—which is expected to create at least 350 neDaiichiby 2030—will equip the site to develop and manufacture future ADCs targeting malignancies like breast, lung and stomach cancers, Daiichi said in a recent press release.
The expansion process has already kicked off, with work on the project expected to wrap up by 2030 “at the latest,” Daiichi said. The new Amalignanciescture breast, lung and stomach cancerslaDaiichi completion by the end of 2026.
Once the site’s ADC facilities are up and running, Daiichi figures it will “most likely rise to the top league of biDaiichiompanies” in the region.
With a legacy spADCing more than 60 years, the PfafDaiichin site contributes “significantly” to Daiichi Sankyo’s global production capacity, the company says on its European website. Traditionally, the site has focused on manufacturing and developing medicines for cardiovascular diseases, including the stroke, thrombosis and pulmonary embolism drug edoxaban and the olmesartan product line for hypertension.
Aside from adding ADC capabilities, the expansion has been tipped to boost capacity for the PfafDaiichi Sankyos bread-and-butter work in cardiovascular disease. The investment will also strengthen the site’s quality assurance and logistics and help bring more renewcardiovascular diseasesichi added.strokethrombosispulmonary embolismedoxabanolmesartanhypertension
The site manufactuADC both active pharmaceutical ingredients and solid dose forms like tablets and film-coated capsules, which Daiichi shcardiovascular diseaseto more than 50 countries.Daiichi
“The fact that we will focus more on oncological therapies in Pfaffenhofen in the future is positive in two respects,” MatthiasDaiichiDaiichi’s site manager at the facility, said in a statement. “On the one hand, we can make a significant contribution to the increased global demand for ADC cancer therapies. On the other hand, we are demonstrating our future viability and the top quality that we provide here.”
The ADC field has been on the rise in recent years, yielding investments and acquisitions across the biopharma industry. While companiDaiichi Pfizer and Roche originally beat Daiichi to the regulatory finish line with their own ADCs, Daiichi and its AstraZeneca-partnered treatment Enhertu hcancerput the modality on the map.
Daiichi is slated to keep that winning streak rolling through the rest of the decade, too, analysts at GlobalData predicted last summer. The aPfizers expRocheaiichi’s ADC saleDaiichitop $10 billion by 2029, well ahead of the respectivDaiichibillion aAstraZenecalion GlobalData figurEnhertuen and Roche will generate with their ADCs in that same span.
At the time, Daiichi said the merger was neDaiichi to “stably supplADCADCs and accelerate the development of new modalities.Daiichi Sankyo PropharmaDaiichi Sankyo Chemical Pharma
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。